FMP
Savara Inc.
SVRA
NASDAQ
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
4.7 USD
-0.11 (-2.34%)
About
ceo
Mr. Matthew Pauls J.D., M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://www.savarapharma.com
exchange
NASDAQ
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
CIK
0001160308
ISIN
US8051111016
CUSIP
805111101
Address
Building III
Phone
512 614 1848
Country
US
Employee
37
IPO Date
Apr 28, 2017
Key Executives
